2i0e: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="2i0e" size="450" color="white" frame="true" align="right" spinBox="true" caption="2i0e, resolution 2.60Å" /> '''Structure of cataly...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:2i0e.gif|left|200px]]<br />
[[Image:2i0e.gif|left|200px]]<br /><applet load="2i0e" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2i0e" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2i0e, resolution 2.60&Aring;" />
caption="2i0e, resolution 2.60&Aring;" />
'''Structure of catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor'''<br />
'''Structure of catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor'''<br />


==Overview==
==Overview==
The conventional protein kinase C isoform, PKCII, is a signaling kinase, activated during the hyperglycemic state and has been associated with the, development of microvascular abnormalities associated with diabetes., PKCII, therefore, has been identified as a therapeutic target where, inhibitors of its kinase activity are being pursued for treatment of, microvascular-related diabetic complications. In this report, we describe, the crystal structure of the catalytic domain of PKCbetaII complexed with, an inhibitor at 2.6 A resolution. The kinase domain of PKCbetaII was, cleaved and purified from full-length PKCbetaII expressed in, baculovirus-infected insect cells. The overall kinase domain structure, follows the classical bilobal fold and is in its fully activated, conformation with three well-defined phosphorylated residues: Thr-500, Thr-641, and Ser-660. Different from the crystal structures of, nonconventional PKC isoforms, the C-terminus of the PKCbetaII catalytic, domain is almost fully ordered and features a novel alpha helix in the, turn motif. An ATP-competitive inhibitor, 2-methyl-1H-indol-3-yl-BIM-1, was crystallized with the PKCbetaII catalytic domain as a dimer of two, enzyme-inhibitor complexes. The bound inhibitor adopts a nonplanar, conformation in the ATP-binding site, with the kinase domain taking on an, intermediate, open conformation. This PKCbetaII-inhibitor complex, represents the first structural description of any conventional PKC kinase, domain. Given the pathogenic role of PKCbetaII in the development of, diabetic complications, this structure can serve as a template for the, rational design of inhibitors as potential therapeutic agents.
The conventional protein kinase C isoform, PKCII, is a signaling kinase activated during the hyperglycemic state and has been associated with the development of microvascular abnormalities associated with diabetes. PKCII, therefore, has been identified as a therapeutic target where inhibitors of its kinase activity are being pursued for treatment of microvascular-related diabetic complications. In this report, we describe the crystal structure of the catalytic domain of PKCbetaII complexed with an inhibitor at 2.6 A resolution. The kinase domain of PKCbetaII was cleaved and purified from full-length PKCbetaII expressed in baculovirus-infected insect cells. The overall kinase domain structure follows the classical bilobal fold and is in its fully activated conformation with three well-defined phosphorylated residues: Thr-500, Thr-641, and Ser-660. Different from the crystal structures of nonconventional PKC isoforms, the C-terminus of the PKCbetaII catalytic domain is almost fully ordered and features a novel alpha helix in the turn motif. An ATP-competitive inhibitor, 2-methyl-1H-indol-3-yl-BIM-1, was crystallized with the PKCbetaII catalytic domain as a dimer of two enzyme-inhibitor complexes. The bound inhibitor adopts a nonplanar conformation in the ATP-binding site, with the kinase domain taking on an intermediate, open conformation. This PKCbetaII-inhibitor complex represents the first structural description of any conventional PKC kinase domain. Given the pathogenic role of PKCbetaII in the development of diabetic complications, this structure can serve as a template for the rational design of inhibitors as potential therapeutic agents.


==About this Structure==
==About this Structure==
2I0E is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with PDS as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Protein_kinase_C Protein kinase C], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.13 2.7.11.13] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2I0E OCA].  
2I0E is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=PDS:'>PDS</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Protein_kinase_C Protein kinase C], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.13 2.7.11.13] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2I0E OCA].  


==Reference==
==Reference==
Line 15: Line 14:
[[Category: Protein kinase C]]
[[Category: Protein kinase C]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Grodsky, N.B.]]
[[Category: Grodsky, N B.]]
[[Category: Love, R.L.]]
[[Category: Love, R L.]]
[[Category: PDS]]
[[Category: PDS]]
[[Category: protein kinase c]]
[[Category: protein kinase c]]
Line 22: Line 21:
[[Category: serine/threonine protein kinase]]
[[Category: serine/threonine protein kinase]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 22:39:15 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:47:44 2008''